ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Gujarat Terce Laboratories held its 41st Annual General Meeting on August 21, 2026. Members passed resolutions regarding financial statements and director re-appointments.
Gujarat Terce Laboratories issued a corrigendum clarifying the re-appointment tenure of its MD & CEO, Mr. Aalap Prajapati, as three years instead of five.
Gujarat Terce Laboratories Ltd reported revenue from operations of ₹9 Cr (-17.4% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
Gujarat Terce Laboratories will hold a board meeting on 7 August 2026 to approve the unaudited standalone financial results for the quarter ended 30 June 2026.
Gujarat Terce Laboratories Ltd has filed its Annual Report for the financial year 2025-26 and notice of its 41st Annual General Meeting.
Gujarat Terce Laboratories Ltd filed its shareholding pattern as of June 30, 2026, detailing promoter, promoter group and public holdings. No monetary transaction is disclosed.
Gujarat Terce reports a challenging Q4 FY26 with an 8% revenue decline but a return to profitability (PAT 10.1L vs loss). Strategy focuses on brand equity and field productivity.
Gujarat Terce Laboratories scheduled its 41st Annual General Meeting for August 21, 2026. The cut-off date for shareholder e-voting eligibility is fixed for August 14, 2026.
Gujarat Terce Laboratories reported a total revenue of ₹47.81 Crore for FY26. The board also approved the re-appointment of Mr. Aalap Prajapati as Managing Director.
Gujarat Terce Laboratories re-appointed Aalap Prajapati as MD & CEO for five years starting October 2026. The move ensures leadership continuity for the pharmaceutical firm.
Gujarat Terce Laboratories Ltd reported revenue from operations of ₹11.4 Cr (-7.3% YoY) and net profit of ₹0.1 Cr for Q4 FY26.
Gujarat Terce Laboratories reported annual standalone revenue of ₹47.81 Crore for FY26. The board approved these audited results and noted an unmodified statutory audit opinion.
Gujarat Terce Laboratories submitted its Annual Secretarial Compliance Report for FY 2025-26. The report by Pinakin Shah & Co. indicates full regulatory compliance with no deviations.
Gujarat Terce Laboratories scheduled a board meeting for May 27, 2026. Directors will approve annual audited financial results for the year ended March 31, 2026.